Endothelial-mesenchymal transition drives expression of CD44 variant and xCT in pulmonary hypertension

Sarasa Isobe, Masaharu Kataoka, Jin Endo, Hidenori Moriyama, Shogo Okazaki, Kenji Tsuchihashi, Yoshinori Katsumata, Tsunehisa Yamamoto, Kohsuke Shirakawa, Naohiro Yoshida, Masayuki Shimoda, Tomohiro Chiba, Takashi Masuko, Yoji Hakamata, Eiji Kobayashi, Hideyuki Saya, Keiichi Fukuda, Motoaki Sano

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) pathogenesis shares similarities with carcinogenesis. One CD44 variant (CD44v) isoform, CD44v8-10, binds to and stabilizes the cystine transporter subunit (xCT), producing reduced glutathione and thereby enhancing the antioxidant defense of cancer stem cells. Pharmacological inhibition of xCT by sulfasalazine suppresses tumor growth, survival, and resistance to chemotherapy. We investigated whether the CD44v-xCT axis contributes to PAH pathogenesis. CD44v was predominantly expressed on endothelial-to-mesenchymal transition (EndMT)-like cells in the neointimal layer of PAH affected pulmonary arterioles. In vitro, CD44 standard form and CD44v were induced as a result of EndMT. Among human pulmonary artery endothelial cells that have undergone EndMT, CD44v+ cells showed high levels of xCT expression on their cell surfaces and high concentrations of glutathione for survival. This made CD44v+ cells the most vulnerable target for sulfasalazine. CD44v+xCThi cells showed the highest expression levels of proinflammatory cytokines, antioxidant enzymes, antiapoptotic molecules, and cyclin-dependent kinase inhibitors. In the Sugen5416/hypoxia mouse model, CD44v+ cells were present in the thickened pulmonary vascular wall. The administration of sulfasalazine started either at the same time as "Sugen5416" administration (a prevention model) or after the development of pulmonary hypertension (a reversal model) attenuated the muscularization of the pulmonary vessels, decreased the expression of markers of inflammation, and reduced the right ventricular systolic pressure, while reducing CD44v+ cells. In conclusion, CD44v+xCThi cells appear during EndMT and in pulmonary hypertension tissues. Sulfasalazine is expected to be a novel therapeutic agent for PAH, most likely targeting EndMT-derived CD44v+xCThi cells.

Original languageEnglish
Pages (from-to)367-379
Number of pages13
JournalAmerican journal of respiratory cell and molecular biology
Volume61
Issue number3
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Sulfasalazine
Pulmonary Hypertension
Glutathione
Antioxidants
Chemotherapy
Cystine
Cyclin-Dependent Kinases
Endothelial cells
Stem cells
Tumors
Lung
Protein Isoforms
Tissue
Cytokines
Molecules
Enzymes
Survival
Neoplastic Stem Cells
Arterioles
Ventricular Pressure

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Clinical Biochemistry
  • Cell Biology

Cite this

Endothelial-mesenchymal transition drives expression of CD44 variant and xCT in pulmonary hypertension. / Isobe, Sarasa; Kataoka, Masaharu; Endo, Jin; Moriyama, Hidenori; Okazaki, Shogo; Tsuchihashi, Kenji; Katsumata, Yoshinori; Yamamoto, Tsunehisa; Shirakawa, Kohsuke; Yoshida, Naohiro; Shimoda, Masayuki; Chiba, Tomohiro; Masuko, Takashi; Hakamata, Yoji; Kobayashi, Eiji; Saya, Hideyuki; Fukuda, Keiichi; Sano, Motoaki.

In: American journal of respiratory cell and molecular biology, Vol. 61, No. 3, 01.01.2019, p. 367-379.

Research output: Contribution to journalArticle

Isobe, S, Kataoka, M, Endo, J, Moriyama, H, Okazaki, S, Tsuchihashi, K, Katsumata, Y, Yamamoto, T, Shirakawa, K, Yoshida, N, Shimoda, M, Chiba, T, Masuko, T, Hakamata, Y, Kobayashi, E, Saya, H, Fukuda, K & Sano, M 2019, 'Endothelial-mesenchymal transition drives expression of CD44 variant and xCT in pulmonary hypertension', American journal of respiratory cell and molecular biology, vol. 61, no. 3, pp. 367-379. https://doi.org/10.1165/rcmb.2018-0231OC
Isobe, Sarasa ; Kataoka, Masaharu ; Endo, Jin ; Moriyama, Hidenori ; Okazaki, Shogo ; Tsuchihashi, Kenji ; Katsumata, Yoshinori ; Yamamoto, Tsunehisa ; Shirakawa, Kohsuke ; Yoshida, Naohiro ; Shimoda, Masayuki ; Chiba, Tomohiro ; Masuko, Takashi ; Hakamata, Yoji ; Kobayashi, Eiji ; Saya, Hideyuki ; Fukuda, Keiichi ; Sano, Motoaki. / Endothelial-mesenchymal transition drives expression of CD44 variant and xCT in pulmonary hypertension. In: American journal of respiratory cell and molecular biology. 2019 ; Vol. 61, No. 3. pp. 367-379.
@article{81f92c1726204090a800670225cbe8fe,
title = "Endothelial-mesenchymal transition drives expression of CD44 variant and xCT in pulmonary hypertension",
abstract = "Pulmonary arterial hypertension (PAH) pathogenesis shares similarities with carcinogenesis. One CD44 variant (CD44v) isoform, CD44v8-10, binds to and stabilizes the cystine transporter subunit (xCT), producing reduced glutathione and thereby enhancing the antioxidant defense of cancer stem cells. Pharmacological inhibition of xCT by sulfasalazine suppresses tumor growth, survival, and resistance to chemotherapy. We investigated whether the CD44v-xCT axis contributes to PAH pathogenesis. CD44v was predominantly expressed on endothelial-to-mesenchymal transition (EndMT)-like cells in the neointimal layer of PAH affected pulmonary arterioles. In vitro, CD44 standard form and CD44v were induced as a result of EndMT. Among human pulmonary artery endothelial cells that have undergone EndMT, CD44v+ cells showed high levels of xCT expression on their cell surfaces and high concentrations of glutathione for survival. This made CD44v+ cells the most vulnerable target for sulfasalazine. CD44v+xCThi cells showed the highest expression levels of proinflammatory cytokines, antioxidant enzymes, antiapoptotic molecules, and cyclin-dependent kinase inhibitors. In the Sugen5416/hypoxia mouse model, CD44v+ cells were present in the thickened pulmonary vascular wall. The administration of sulfasalazine started either at the same time as {"}Sugen5416{"} administration (a prevention model) or after the development of pulmonary hypertension (a reversal model) attenuated the muscularization of the pulmonary vessels, decreased the expression of markers of inflammation, and reduced the right ventricular systolic pressure, while reducing CD44v+ cells. In conclusion, CD44v+xCThi cells appear during EndMT and in pulmonary hypertension tissues. Sulfasalazine is expected to be a novel therapeutic agent for PAH, most likely targeting EndMT-derived CD44v+xCThi cells.",
author = "Sarasa Isobe and Masaharu Kataoka and Jin Endo and Hidenori Moriyama and Shogo Okazaki and Kenji Tsuchihashi and Yoshinori Katsumata and Tsunehisa Yamamoto and Kohsuke Shirakawa and Naohiro Yoshida and Masayuki Shimoda and Tomohiro Chiba and Takashi Masuko and Yoji Hakamata and Eiji Kobayashi and Hideyuki Saya and Keiichi Fukuda and Motoaki Sano",
year = "2019",
month = "1",
day = "1",
doi = "10.1165/rcmb.2018-0231OC",
language = "English",
volume = "61",
pages = "367--379",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "3",

}

TY - JOUR

T1 - Endothelial-mesenchymal transition drives expression of CD44 variant and xCT in pulmonary hypertension

AU - Isobe, Sarasa

AU - Kataoka, Masaharu

AU - Endo, Jin

AU - Moriyama, Hidenori

AU - Okazaki, Shogo

AU - Tsuchihashi, Kenji

AU - Katsumata, Yoshinori

AU - Yamamoto, Tsunehisa

AU - Shirakawa, Kohsuke

AU - Yoshida, Naohiro

AU - Shimoda, Masayuki

AU - Chiba, Tomohiro

AU - Masuko, Takashi

AU - Hakamata, Yoji

AU - Kobayashi, Eiji

AU - Saya, Hideyuki

AU - Fukuda, Keiichi

AU - Sano, Motoaki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Pulmonary arterial hypertension (PAH) pathogenesis shares similarities with carcinogenesis. One CD44 variant (CD44v) isoform, CD44v8-10, binds to and stabilizes the cystine transporter subunit (xCT), producing reduced glutathione and thereby enhancing the antioxidant defense of cancer stem cells. Pharmacological inhibition of xCT by sulfasalazine suppresses tumor growth, survival, and resistance to chemotherapy. We investigated whether the CD44v-xCT axis contributes to PAH pathogenesis. CD44v was predominantly expressed on endothelial-to-mesenchymal transition (EndMT)-like cells in the neointimal layer of PAH affected pulmonary arterioles. In vitro, CD44 standard form and CD44v were induced as a result of EndMT. Among human pulmonary artery endothelial cells that have undergone EndMT, CD44v+ cells showed high levels of xCT expression on their cell surfaces and high concentrations of glutathione for survival. This made CD44v+ cells the most vulnerable target for sulfasalazine. CD44v+xCThi cells showed the highest expression levels of proinflammatory cytokines, antioxidant enzymes, antiapoptotic molecules, and cyclin-dependent kinase inhibitors. In the Sugen5416/hypoxia mouse model, CD44v+ cells were present in the thickened pulmonary vascular wall. The administration of sulfasalazine started either at the same time as "Sugen5416" administration (a prevention model) or after the development of pulmonary hypertension (a reversal model) attenuated the muscularization of the pulmonary vessels, decreased the expression of markers of inflammation, and reduced the right ventricular systolic pressure, while reducing CD44v+ cells. In conclusion, CD44v+xCThi cells appear during EndMT and in pulmonary hypertension tissues. Sulfasalazine is expected to be a novel therapeutic agent for PAH, most likely targeting EndMT-derived CD44v+xCThi cells.

AB - Pulmonary arterial hypertension (PAH) pathogenesis shares similarities with carcinogenesis. One CD44 variant (CD44v) isoform, CD44v8-10, binds to and stabilizes the cystine transporter subunit (xCT), producing reduced glutathione and thereby enhancing the antioxidant defense of cancer stem cells. Pharmacological inhibition of xCT by sulfasalazine suppresses tumor growth, survival, and resistance to chemotherapy. We investigated whether the CD44v-xCT axis contributes to PAH pathogenesis. CD44v was predominantly expressed on endothelial-to-mesenchymal transition (EndMT)-like cells in the neointimal layer of PAH affected pulmonary arterioles. In vitro, CD44 standard form and CD44v were induced as a result of EndMT. Among human pulmonary artery endothelial cells that have undergone EndMT, CD44v+ cells showed high levels of xCT expression on their cell surfaces and high concentrations of glutathione for survival. This made CD44v+ cells the most vulnerable target for sulfasalazine. CD44v+xCThi cells showed the highest expression levels of proinflammatory cytokines, antioxidant enzymes, antiapoptotic molecules, and cyclin-dependent kinase inhibitors. In the Sugen5416/hypoxia mouse model, CD44v+ cells were present in the thickened pulmonary vascular wall. The administration of sulfasalazine started either at the same time as "Sugen5416" administration (a prevention model) or after the development of pulmonary hypertension (a reversal model) attenuated the muscularization of the pulmonary vessels, decreased the expression of markers of inflammation, and reduced the right ventricular systolic pressure, while reducing CD44v+ cells. In conclusion, CD44v+xCThi cells appear during EndMT and in pulmonary hypertension tissues. Sulfasalazine is expected to be a novel therapeutic agent for PAH, most likely targeting EndMT-derived CD44v+xCThi cells.

UR - http://www.scopus.com/inward/record.url?scp=85071097669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071097669&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2018-0231OC

DO - 10.1165/rcmb.2018-0231OC

M3 - Article

C2 - 30897333

AN - SCOPUS:85071097669

VL - 61

SP - 367

EP - 379

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 3

ER -